The Emerging Role of lncRNAs in Cancer Therapy DOI Creative Commons
Naveed Shuja

Developmental medico-life-sciences, Год журнала: 2024, Номер 1(9), С. 1 - 3

Опубликована: Дек. 18, 2024

In recent decades, cancer biology has witnessed unprecedented advances in the study of biology, and long noncoding RNAs (lncRNAs) are now known to play central roles progression, regulation, therapeutic response[1]. Since their discovery, lncRNAs have been quickly becoming focus oncology research, given critical gene expression tumor microenvironment therapy resistance, once thought as transcriptional noise. These discoveries hold promise for developing novel diagnostic biomarkers well targeted therapies, furthering field precision oncology[2]. Types lncRNAs: LncRNAs can be grouped according location genome, structure, mode action. The major types include: Intergenic (lincRNAs): They transcribed from regions between protein-coding genes do not require regulation adjacent genes[3]. Intronic originate introns either regulate host or independent. Sense transcribe same strand region genes, but code nothing[4]. Antisense opposite through complementary base-pairing. Enhancer (eRNAs): were enhancer act enhance transcription nearby genes. Circular (circRNAs): CircRNAs highly stable formed by back-splicing events, competing with miRNAs binding regulating This classification underscores structural complexity versatility diversity lncRNAs[3]. Functional Complexity class comprises diverse that longer than 200 nucleotides. As a result, they show exquisite at multiple levels, including epigenetic, transcriptional, post-transcriptional, interactions DNA, RNA, proteins. ability functionally plasticity allows them orchestrate key biological processes such proliferation, apoptosis, metastasis, angiogenesis, immune evasion[5]. Importantly, dysregulated several cancers lung, breast, colorectal, head neck squamous cell carcinoma (HNSCC), making oncogenes suppressors. last few years also revealed may modulate signaling pathways PI3K/AKT, Wnt/β-catenin, p53, NF-κB influence survival, drug directly. For example, lncRNA MALAT1 HOTAIR well-established oncogenic associated metastasis poor prognosis, while MEG3 GAS5 suppressor induce apoptosis inhibit proliferation. intricate context-specific functions progression underscored this dual nature[6]. Therapy Resistance LncRNAs: resistance is one impediments treatment, frequently resulting disease recurrence patient outcomes. More more evidence showing mediators chemotherapy, radiotherapy, therapies. mechanisms include epithelial-mesenchymal transition (EMT), autophagy efflux pump modulation, inhibition[7]. an H19 shown confer tyrosine kinase inhibitors (TKIs) lung upregulating enzyme glycolysis, PKM2. Like UCA1 PVT1, promote cisplatin sponging suppressive activating pro-survival pathways. If we target these resistance-associated lncRNAs, sensitize cells improve effectiveness[8]. Biomarkers Therapeutic Targets: unique profiles high tissue specificity, thus promising candidates biomarkers. Detection fluids possible provide minimally invasive prognostic tools. There already PCA3 (prostate cancer) HULC (hepatocellular carcinoma) potential used markers clinical translation[9]. addition, new strategy targeting lncRNAs. Silencing restoration performed technologies RNA interference (RNAi), antisense oligonucleotides (ASO), CRISPR/Cas systems. stability bioavailability therapeutics further enhanced nanoparticle-based delivery systems hope successful practice[10]. Future Perspectives Challenges: Despite promise, there still challenges overcome Current context-dependent understood, no effective system exists facilitate application. personalized approaches lncRNA-based therapies needed heterogeneity cancer[11]. research should unweave molecular cancer, identify reliable response, explore drugs. To bring patients, collaborative efforts combine multi-omics technologies, artificial intelligence, trials will critical[12, 13]. CONCLUSION emerging agent, adding paradigm biology. regulators tumorigenesis, great diagnosis, treatment. advance day transform patients fighting formidable disease.

Язык: Английский

The impact of platelets on the metastatic potential of tumour cells DOI Creative Commons
Hans Raskov, Adile Orhan, Mette Ø. Agerbæk

и другие.

Heliyon, Год журнала: 2024, Номер 10(14), С. e34361 - e34361

Опубликована: Июль 1, 2024

In cancer, activation of platelets by tumor cells is critical to disease progression. Development precise antiplatelet targeting may improve outcomes from anticancer therapy.Alongside a distinct shift in functionality such as pro-metastatic and pro-coagulant properties, platelet production often accelerated significantly early carcinogenesis the cancer-associated thrombocytosis increases risk metastasis formation thromboembolic events. Tumor-activated facilitate proliferation migrating shield them immune surveillance physical stress during circulation. Additionally, platelet-tumor cell interactions promote intravasation, intravascular arrest, extravasation through repertoire adhesion molecules, growth factors angiogenic factors. Particularly, presence circulating (CTC) clusters association with negative prognostic indicator.The contribution metastatic process an area intense investigation this review provides overview advances understanding their Also, we potential interfere process.

Язык: Английский

Процитировано

4
The m6A Reader YTHDC2 Restrains Endometrial Cancer Progression Through Suppressing Hedgehog Signaling Pathway DOI
Xinyan Zhang,

Man Gao,

Hongyun Ma

и другие.

Pathology - Research and Practice, Год журнала: 2025, Номер 269, С. 155879 - 155879

Опубликована: Фев. 28, 2025

Язык: Английский

Процитировано

0
Decoding intricate interactions between m6A modification with mRNAs and non-coding RNAs in cervical cancer: Molecular mechanisms and clinical implications DOI
Xuefei Liu, Lizhi Zhang, Ji Chen

и другие.

Cellular Signalling, Год журнала: 2025, Номер unknown, С. 111745 - 111745

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population DOI Open Access

Cecil Sorin Mirea,

Michael Schenker,

Bianca Petre-Mandache

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 3078 - 3078

Опубликована: Март 27, 2025

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality, influenced by both genetic epigenetic factors. Long non-coding RNAs (lncRNAs) such as GAS5 CASC8 have been implicated in susceptibility. This study aimed to assess the association rs145204276 ins/del rs10505477 A>G polymorphisms with CRC risk Romanian population. A case-control was conducted, including 156 patients 195 healthy controls. Genotyping for performed using real-time PCR, evaluated logistic regression calculate odds ratios (OR) 95% confidence intervals (CI). The carriers del allele significantly associated increased (OR: 2.13, CI: 1.24-3.63, p = 0.005) dominant model. In subgroup analysis, polymorphism restricted distal colon cases 2.98, 1.57-5.66, 0.001), advanced tumor stages (III + IV) 2.54, 1.31-4.91, 0.007), poorly differentiated tumors (G3) 3.98, 1.49-10.59, 0.009). No significant correlation found polymorphism. may influence susceptibility, particularly stages. However, showed no this cohort.

Язык: Английский

Процитировано

0
Regulation of immune-mediated chemoresistance in cancer by lncRNAs: an in-depth review of signaling pathways DOI
Saade Abdalkareem Jasim, Farag M. A. Altalbawy, Subasini Uthirapathy

и другие.

Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 9, 2025

Язык: Английский

Процитировано

0
EXO1 as a potential biomarker for prognosis, immune infiltration, and immunotherapy in pan-cancer analysis DOI
Jikang Wang, Fubo Wang,

Haoxuan Huang

и другие.

Functional & Integrative Genomics, Год журнала: 2025, Номер 25(1)

Опубликована: Апрель 11, 2025

Язык: Английский

Процитировано

0
Regulatory RNAs: role as scaffolds assembling protein complexes and their epigenetic deregulation DOI Creative Commons
Palmiro Poltronieri

Exploration of Targeted Anti-tumor Therapy, Год журнала: 2024, Номер 5(4), С. 841 - 876

Опубликована: Июль 22, 2024

Recently, new data have been added to the interaction between non-coding RNAs (ncRNAs) and epigenetic machinery. Epigenetics includes enzymes involved in DNA methylation, histone modifications, RNA mechanisms underlying chromatin structure, repressive states, active states operating transcription. The main focus is on long ncRNAs (lncRNAs) acting as scaffolds assemble protein complexes. This review does not cover RNA's role sponging microRNAs, or decoy functions. Several lncRNAs were shown regulate activation repression by interacting with Polycomb complexes mixed-lineage leukemia (MLL) activating Various groups reported enhancer of zeste homolog 2 (EZH2) interactions regulatory RNAs. Knowledge function these opens perspective develop therapeutics for cancer treatment. Lastly, interplay epitranscriptomic modifications cancers paves way targets therapy. approach inhibit epitrascriptomics-regulated may bring compounds therapeuticals various types cancer.

Язык: Английский

Процитировано

1
Epigenetics of Conjunctival Melanoma: Current Knowledge and Future Directions DOI Open Access

Karin Flick,

Hakan Demirci, F. Yesim Demirci

и другие.

Cancers, Год журнала: 2024, Номер 16(21), С. 3687 - 3687

Опубликована: Окт. 31, 2024

The purpose of this article is to provide a literature review the epigenetic understanding conjunctival melanoma (CM), with primary focus on current gaps in knowledge and future directions research. CM rare aggressive cancer that predominantly affects older adults. Local recurrences distant metastases commonly occur patients; however, their prediction management remain challenging. Hence, there currently an unmet need for useful biomarkers more effective treatments improve clinical outcomes these patients. Like other cancers, occurrence prognosis are believed be influenced by multiple genetic factors contribute tumor development/progression/recurrence/spread, immune evasion, primary/acquired resistance therapies. Epigenetic alterations may involve changes chromatin conformation/accessibility, post-translational histone modifications or use variants, DNA methylation, levels/functions short (small) long non-coding RNAs (ncRNAs), RNA modifications. While recent years have witnessed rapid increase available technologies modulation-based treatment options, which has enabled development/implementation various epi-drugs field, remains limited due relatively small number studies published date. These primarily investigated ncRNA (e.g., miRNA circRNA) expression, methylation. initial investigations revealed some potential and/or therapeutic targets, they had limitations, findings warrant replication independent larger studies/samples. In summary, in-depth epigenetics largely incomplete but essential advancing our molecular improving management/outcomes disease.

Язык: Английский

Процитировано

1
Diverse RNA methylation patterns in neutrophils: key drivers in hepatocellular carcinoma DOI
Guangming Xu, Yifan Jiang,

Zhenhua Tu

и другие.

Clinical & Translational Oncology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 2, 2024

Язык: Английский

Процитировано

1
The Emerging Role of lncRNAs in Cancer Therapy DOI Creative Commons
Naveed Shuja

Developmental medico-life-sciences, Год журнала: 2024, Номер 1(9), С. 1 - 3

Опубликована: Дек. 18, 2024

In recent decades, cancer biology has witnessed unprecedented advances in the study of biology, and long noncoding RNAs (lncRNAs) are now known to play central roles progression, regulation, therapeutic response[1]. Since their discovery, lncRNAs have been quickly becoming focus oncology research, given critical gene expression tumor microenvironment therapy resistance, once thought as transcriptional noise. These discoveries hold promise for developing novel diagnostic biomarkers well targeted therapies, furthering field precision oncology[2]. Types lncRNAs: LncRNAs can be grouped according location genome, structure, mode action. The major types include: Intergenic (lincRNAs): They transcribed from regions between protein-coding genes do not require regulation adjacent genes[3]. Intronic originate introns either regulate host or independent. Sense transcribe same strand region genes, but code nothing[4]. Antisense opposite through complementary base-pairing. Enhancer (eRNAs): were enhancer act enhance transcription nearby genes. Circular (circRNAs): CircRNAs highly stable formed by back-splicing events, competing with miRNAs binding regulating This classification underscores structural complexity versatility diversity lncRNAs[3]. Functional Complexity class comprises diverse that longer than 200 nucleotides. As a result, they show exquisite at multiple levels, including epigenetic, transcriptional, post-transcriptional, interactions DNA, RNA, proteins. ability functionally plasticity allows them orchestrate key biological processes such proliferation, apoptosis, metastasis, angiogenesis, immune evasion[5]. Importantly, dysregulated several cancers lung, breast, colorectal, head neck squamous cell carcinoma (HNSCC), making oncogenes suppressors. last few years also revealed may modulate signaling pathways PI3K/AKT, Wnt/β-catenin, p53, NF-κB influence survival, drug directly. For example, lncRNA MALAT1 HOTAIR well-established oncogenic associated metastasis poor prognosis, while MEG3 GAS5 suppressor induce apoptosis inhibit proliferation. intricate context-specific functions progression underscored this dual nature[6]. Therapy Resistance LncRNAs: resistance is one impediments treatment, frequently resulting disease recurrence patient outcomes. More more evidence showing mediators chemotherapy, radiotherapy, therapies. mechanisms include epithelial-mesenchymal transition (EMT), autophagy efflux pump modulation, inhibition[7]. an H19 shown confer tyrosine kinase inhibitors (TKIs) lung upregulating enzyme glycolysis, PKM2. Like UCA1 PVT1, promote cisplatin sponging suppressive activating pro-survival pathways. If we target these resistance-associated lncRNAs, sensitize cells improve effectiveness[8]. Biomarkers Therapeutic Targets: unique profiles high tissue specificity, thus promising candidates biomarkers. Detection fluids possible provide minimally invasive prognostic tools. There already PCA3 (prostate cancer) HULC (hepatocellular carcinoma) potential used markers clinical translation[9]. addition, new strategy targeting lncRNAs. Silencing restoration performed technologies RNA interference (RNAi), antisense oligonucleotides (ASO), CRISPR/Cas systems. stability bioavailability therapeutics further enhanced nanoparticle-based delivery systems hope successful practice[10]. Future Perspectives Challenges: Despite promise, there still challenges overcome Current context-dependent understood, no effective system exists facilitate application. personalized approaches lncRNA-based therapies needed heterogeneity cancer[11]. research should unweave molecular cancer, identify reliable response, explore drugs. To bring patients, collaborative efforts combine multi-omics technologies, artificial intelligence, trials will critical[12, 13]. CONCLUSION emerging agent, adding paradigm biology. regulators tumorigenesis, great diagnosis, treatment. advance day transform patients fighting formidable disease.

Язык: Английский

Процитировано

0